Design Therapeutics, Inc. (DSGN)
DSGNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$10.80
+0.5900 (+5.78%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $691.59m
- P/E
- –
- EPS, last 4 quarters
- $-1.20
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.68 to $17.25
- Average volume
- 593.6k
- Previous close
- $10.21
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $21.60, +100.0% from here
Earnings
next estimate $-0.5000Next report
Dec 2025
+28.9%
Mar 2026
+19.4%
Jun 2026
+11.1%
Sep 2026
+15.8%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$19.31m | -$18.17m | -$19.71m | -$22.18m |
| Net income | -$17.00m | -$16.00m | -$17.64m | -$20.16m |
News
8 latest- Design Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 5 days ago
- FDA Extends Review Time for AZN's Camizestrant Combo in Breast CancerZacks · May 27, 2026
- AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast CancerZacks · May 25, 2026
- Notable Tuesday Option Activity: AEVA, RKLB, DSGNBNK Invest · May 19, 2026
- Design Therapeutics Posts Four-Week RESTORE-FA Gains In Friedreich Ataxia; Stock Up RTTNews · May 18, 2026
- Design Therapeutics To Present RESTORE-FA Trial Data Today; Stock Up RTTNews · May 18, 2026
- Design Therapeutics (DSGN) Price Target Increased by 17.05% to 17.51Fintel · May 14, 2026
- Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know Zacks · May 11, 2026
The company
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company's GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- designtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.